fibrosing interstitial lung disease

Category:

SOP Numbers	Date of Commencement	Incorporated Material	Status
Reasonable Hypothesis	Date of Commencement	Incorporated Material	Status		Balance of Probabilities
85/2021 85/2021	86/2021 86/2021	20/09/2021	Guide to Calculation of Cumulative Equivalent Dose ARPANSA 2 August 2017	Current	Principal

SOP Numbers		Date of Commencement	Status
Reasonable Hypothesis	Balance of Probabilities	Date of Commencement	Status
58/2017 58/2017	58/2017 58/2017	18/09/2017	Revoked	Amendment
53/2013	54/2013	18/09/2017	Revoked	Compilation
53/2013 53/2013	54/2013 54/2013	04/09/2013	Revoked	Principal
66/2012	67/2012	05/09/2012	Revoked	Amendment
79/2011	80/2011	25/05/2011	Revoked	Amendment
59/2010	60/2010	30/06/2010	Revoked	Amendment
35/2009	36/2009	06/05/2009	Revoked	Principal
previously known as: idiopathic fibrosing alveolitis
15/1998	16/1998	08/04/1998	Revoked	Principal

Subject	Documents	Relevant SOPs	Date	Comment
Explanatory Statements tabled in Houses of Parliament	SOP Explanatory Statement No. 85 of 2021 - RH - fibrosing interstitial lung disease - 20 September 2021 SOP Explanatory Statement No. 86 of 2021 - BP - fibrosing interstitial lung disease - 20 September 2021	85/2021 86/2021	20/09/2021
Reference List	Reference list - fibrosing interstitial lung disease - RMA meeting August 2021	85/2021 86/2021	04/08/2021